Stanford neurobiologist Carla Shatz, famous for discovering how neural connections develop early in life, is using that knowledge to work on the problem of how they can later deteriorate from Alzheimer’s disease.
Scientists in the lab of chemical engineer Monther Abu-Remaileh are uncovering the cellular functions that go awry in degenerative brain disorders and identifying therapies that could treat them.
Research supported by a Knight Initiative Catalyst Grant explores whether targeting pathways related to the brain’s “chill-out” system could restore youthful resilience and improve cognitive function.
Q&A with Wu Tsai Neuro affiliate Kathleen Poston about her work past and present on Parkinson’s disease. Poston studies the pathophysiology underlying the cognitive, behavioral and motor symptoms characteristic of Parkinson’s.
A few closely related drugs, all squarely aimed at treating Alzheimer’s disease, have served up what can be charitably described as a lackadaisical performance. Wu Tsai Neuro and Knight Initiative affiliate Mike Greicius explains why.
Students learned how behind every success is a story of perseverance, frustration, and failure in a fall quarter class featuring Stanford’s own Nobel laureates and MacArthur “genius” fellows, including Wu Tsai Neuro affiliate Michelle Monje.
Working in the Gibson Lab, Brain Resilience Postdoc Scholar Daniela Rojo looks at how abnormal changes in gene activity impact the cells involved in producing myelin to the extent that it leads to neurodegeneration in the brain.
By studying the independent evolution of the cephalopod nervous system, researchers like Matt McCoy seek to look past the differences to see common features that could teach us fundamental truths about the evolution of intelligence itself.
Katrin Andreasson discusses how immune cells can cause harmful brain inflammation and contribute to the development of neurodegenerative diseases like Alzheimer’s disease.
